Zacks: Brokers Expect HealthEquity, Inc. (NASDAQ: HQY) to Report Quarterly Sales of $ 186.25 Million

0


Equity research analysts predict that HealthEquity, Inc. (NASDAQ: HQY) will report sales of $ 186.25 million for the current fiscal quarter, Zacks investment research reports. Six analysts have released earnings estimates for HealthEquity, with the lowest sales estimate at $ 181.29 million and the highest estimate at $ 188.50 million. HealthEquity reported sales of $ 179.35 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.8%. The company is expected to release its next earnings report on Monday, December 6.

On average, analysts expect HealthEquity to report annual sales of $ 761.77 million for the current year, with estimates ranging from $ 756.79 million to $ 778.20 million. For the next fiscal year, analysts expect the company to record sales of $ 844.32 million, with estimates ranging from $ 802.62 million to $ 905.70 million. Zacks Investment Research’s sales calculations are an average based on a survey of seller-side research companies that track HealthEquity.

HealthEquity (NASDAQ: HQY) last reported its results on Tuesday, September 7. The company reported EPS of $ 0.40 for the quarter, beating the consensus estimate of $ 0.36 by $ 0.04. HealthEquity achieved a return on equity of 5.25% and a net margin of 0.10%. The company posted revenue of $ 189.10 million for the quarter, compared to analysts’ estimates of $ 184.99 million. In the same quarter of the previous year, the company achieved EPS of $ 0.29. The company’s revenue for the quarter increased 7.4% from the same quarter last year.

A number of research analysts have weighed in on the company recently. Stephens assumed coverage of HealthEquity in a report on Thursday, July 1. They issued an “overweight” rating and a target price of $ 100.00 on the stock. Raymond James raised his target price on HealthEquity from $ 85 to $ 90.00 and gave the company a “strong buy” rating in a report released Thursday, June 10. Cantor Fitzgerald increased his price target on HealthEquity from $ 82.00 to $ 85 and gave the company an “overweight” rating in a research report published on Tuesday, June 8. Deutsche Bank Aktiengesellschaft lowered its price target on HealthEquity from $ 92.00 to $ 75.00 and set a “buy” rating for the company in a research report published on Tuesday, September 21. Finally, Barrington Research reissued a “buy” note and issued a target price of $ 90.00 on shares of HealthEquity in a research report on Thursday, September 9. Three equity research analysts rated the stock with a conservation rating, seven issued a buy rating, and one gave the company a high buy rating. According to MarketBeat.com, HealthEquity currently has an average rating of “Buy” and a consensus price target of $ 85.70.

(A d)

With sales of Canadian green leaves up 300%

In related news, the director Ian sacks sold 10,000 shares of the company in a transaction that took place on Thursday, July 15. The stock was sold for an average price of $ 76.49, for a total value of $ 764,900.00. As a result of the transaction, the Director now directly owns 149,656 shares of the company, valued at approximately $ 11,447,187.44. The transaction has been disclosed in a legal file with the Securities & Exchange Commission, which can be accessed via this hyperlink. Also, VP William Robert Otten sold 1,850 shares of the company in a transaction that took place on Monday August 2. The shares were sold for an average price of $ 74.47, for a total value of $ 137,769.50. Disclosure of this sale can be found here. During the last quarter, insiders sold 32,700 shares of the company valued at $ 2,288,740. Company insiders own 2.80% of the company’s shares.

Several large investors have recently bought and sold shares of HQY. Envestnet Asset Management Inc. increased its stake in HealthEquity shares by 39.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 29,485 shares of the company valued at $ 2,005,000 after purchasing an additional 8,328 shares in the last quarter. Alliancebernstein LP increased its stake in HealthEquity shares by 3.6% in the 1st quarter. Alliancebernstein LP now owns 201,161 shares of the company valued at $ 13,679,000 after purchasing an additional 7,003 shares in the last quarter. The Swiss National Bank increased its stake in HealthEquity by 1.3% in the first quarter. The Swiss National Bank now owns 175,600 shares of the company valued at $ 11,941,000 after purchasing an additional 2,200 shares in the last quarter. Cibc World Markets Corp bought a new stake in HealthEquity in the 1st quarter valued at $ 605,000. Finally, BNP Paribas Arbitrage SA increased its stake in HealthEquity by 10.3% in the first quarter. BNP Paribas Arbitrage SA now owns 19,545 shares of the company valued at $ 1,329,000 after purchasing an additional 1,822 shares in the last quarter.

Actions of NASDAQ: HQY open at $ 66.01 Wednesday. The company’s 50-day simple moving average is $ 67.42 and its two-hundred-day simple moving average is $ 72.87. The company has a market cap of $ 5.51 billion, a P / E ratio of 6,601.00, a PEG ratio of 5.22 and a beta of 1.37. The company has a leverage ratio of 0.48, a quick ratio of 4.50 and a current ratio of 4.65. HealthEquity has a 52-week low of $ 48.77 and a 52-week high of $ 93.32.

HealthEquity Company Profile

HealthEquity, Inc provides a range of solutions for managing health care accounts. The firm offers its solutions to employers, health plans, brokers, consultants and financial advisers. Its services include HAS, FSA, HRA, DCRA, 401 (k), Commuter, COBRA and HIA. It also offers products such as the Health Savings and Spending Platform, Health Savings Accounts, Investment Advisory Services, Repayment Terms and Health Care Incentives.

Read more: What is the QQQ ETF?

Get a Free Copy of Zacks’ Research Report on HealthEquity (HQY)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Revenue history and estimates for HealthEquity (NASDAQ: HQY)

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in HealthEquity now?

Before you consider HealthEquity, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold … and HealthEquity was not on the list.

While HealthEquity currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Share.

About Author

Leave A Reply